Recent publications on Cancer

Wernli KJ, O’Meara E, Kerlikowske K, Miglioretti D, Muller CY, Onega T, Sprague B, Henderson L, Buist DS. Investigation of mammographic breast density as a risk factor for ovarian cancer. J Nat Cancer Inst. 2014 Jan 1;106(1):djt341. doi: 10.1093/jnci/djt341. Epub 2013 Dec 5. PubMed

Wernli KJ, DeMartini WB, Ichikawa L, Lehman C, Onega TL, Kerlikowske K, Gellar BM, Hofmann M, Yankaskas BC; for the Breast Cancer Surveillance Consortium. Patterns of breast magnetic resonance imaging use in community practice. JAMA Intern Med. 2014 Jan;174(1):125-32. doi: 10.1001/jamainternmed.2013.11963. Epub 2013 Nov 18. PubMed

Wagner EH, Ludman EJ, Aiello Bowles EJ, Penfold R, Reid RJ, Rutter CM, Chubak J, McCorkle R. Nurse navigators in early cancer care: a randomized, controlled trial. J Clin Oncol. 2014 Jan 1;32(1):12-8. doi: 10.1200/JCO.2013.51.7359. Epub 2013 Nov 25. PubMed

Delate T, Won K, Carroll NM, Kushi L, Hornbrook M, Aiello Bowles EJ, Menter A, Loggers ET, Ritzwoller D. Factors associated with first-line bevacizumab use in advanced, non-squamous, non-small cell lung cancer. J Cancer Res Ther. 2014;2(1):1-8. PubMed

Yan J, Lewis DH, Benoit MF, Eary JF, Mankoff DA. 131I therapy using rhTSH stimulation and dosimetry in metastatic malignant struma ovarii. Clin Nucl Med. 2014 Jan;39(1):102-5. doi: 10.1097/RLU.0b013e3182a75cad. Epub 2013 Oct 22. PubMed

Coronado GD, Burdick T, Kapka T, Retecki S, Green BB. Using an automated data-driven EHR-embedded program for mailing FIT kits: lessons from the STOP CRC pilot study. J Gen Pract (Los Angel). 2014 Jan 5;2. pii: 1000141. PubMed

Stout NK, Nekhlyudov L, Li L, Malin ES, Ross-Deganan D, Buist DS, Rosenber MA, Alfisher M, Fletcher SW. Rapid increase in breast magnetic resonance imaging use: trends from 2000-2011. JAMA Intern Med. 2014 Jan;174(1):114-21. doi: 10.1001/jamainternmed.2013.11958. Epub 2013 Nov 18. PubMed

Burnside ES, Lin Y, Munoz Del Rio A, Pickhardt PJ, Wu Y, Strigel RM, Elezaby MA, Kerr EA, Miglioretti DL. Addressing the challenge of assessing physician-level screening performance: mammography as an example.  PLoS One. 2014 Feb 21;9(2):e89418. doi: 10.1371/journal.pone.0089418. PubMed

Sprague BL, Trentham-Dietz A, Hedman CJ, Wang J, Hemming JD, Hampton JM, Buist DS, Bowles EJ, Sisney GS, Burnside ES. Circulating serum xenoestrogens and mammographic breast density.  Breast Cancer Res. 2014 Jan;174(1):25-31. doi: 10.1001/jamainternmed.2013.11074. Erratum in: JAMA Intern Med. 2014 Sep;174(9):1523. Epub 2013 Sep 30. PubMed

Lee FC, Harris W, Cheng HH, Shenoi J, Zhao S, Wang J, Champion T, Izard J, Gore JL, Porter M, Wright JL. Pathologic response rates of gemcitabine/cisplatin versus methotrexate/vinblastine/adriamycin/cisplatin neoadjuvant chemotherapy for muscle invasive urothelial bladder cancer. Adv Urol. 2013;2013:317190. doi: 10.1155/2013/317190. Epub 2013 Dec 8. PubMed

Rutter CM, Johnson EA, Feuer EJ, Knudsen AB, Kuntz KM, Schrag D. Secular trends in colon and rectal cancer relative survival.  J Natl Cancer Inst. 2013 Dec 4;105(23):1806-13. doi: 10.1093/jnci/djt299. Epub Oct 30. PubMed

Onitilo AA, Onesti JK, Single RM, Engel JM, James TA, Aiello Bowles EJ, Feigelson HS, Barney T, McCahill LE. Utilization of neoadjuvant chemotherapy varies in the treatment of women with invasive breast cancer. PLoS One. 2013 Dec 20;8(12):e84535. doi: 10.1371/journal.pone.0084535. PubMed

Taira AV, Merrick GS, Butler WM, Galbreath RW, Fiano R, Wallner KE, Adamovich E. Time to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment. J Contemp Brachytherapy. 2013 Dec;5(4):215-21. doi: 10.5114/jcb.2013.39210. Epub 2013 Dec 3. PubMed

Moyer VA, LeFevre ML, Siu AL, Peters JJ, Baumann JJ, Bibbins-Domingo K, Curry SJ, Ebell M, Flores G, Garcia FA, Cantu AG, Grossman DC, Herzstein J, Nicholson WK, Owens DK, Phillips WR, Pignone MP. Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013 Nov 19;159(10):698-708. doi: 10.7326/0003-4819-159-10-201311190-00717. PubMed

O'Meara ES, Zhu W, Hubbard RA, Braithwaite D, Kerlikowske K, Dittus KL, Geller B, Wernli KJ, Miglioretti DL. Mammographic screening interval in relation to tumor characteristics and false-positive risk by race/ethnicity and age. Cancer. 2013 Nov 15;119(22):3959-67. doi: 10.1002/cncr.28310. Epub 2013 Aug 26. PubMed

Roman M, Hubbard RA, Sebuodegard S, Miglioretti DL, Castells X, Hofvind S. The cumulative risk of false-positive results in the Norwegian Breast Cancer Screening Program: updated results. Cancer. 2013 Nov 15;119(22):3952-8. doi: 10.1002/cncr.28320. Epub 2013 Aug 20. PubMed

Chubak J, Bogart A, Fuller S, Laing SS, Green BB. Uptake and positive predictive value of fecal occult blood tests: a randomized controlled trial. Prev Med. 2013 Nov;57(5):671-8. doi: 10.1016/j.ypmed.2013.08.032. Epub 2013 Sep 9. PubMed

Dittus K, Geller B, Weaver DL, Kerlikowske K, Zhu W, Hubbard R, Braithwaite D, O'Meara ES, Miglioretti DL. Impact of mammography screening interval on breast cancer diagnosis by menopausal status and BMI. J Gen Intern Med. 2013 Nov;28(11):1454-62. doi:10.1007/s11606-013-2507-0. Epub 2013 Jun 13. PubMed

Onitilo AA, Engel JM, James TA, Aiello Bowles EJ, McCahill LE, Feigelson HS. Reply to: Should initial mastectomy rates increase? J Am Coll Surg. 2013 Nov;217(5):960-2. doi: 10.1016/j.jamcollsurg.2013.07.396. PubMed

Mazor KM, Beard RL, Alexander GL, Arora NK, Firneno C, Gaglio B, Greene SM, Lemay CA, Robinson BE, Roblin DW, Walsh K, Street RL Jr, Gallagher TH. Patients' and family members' views on patient-centered communication during cancer care. Psychooncology. 2013 Nov;22(11):2487-95. doi: 10.1002/pon.3317. Epub 2013 Jun 18. PubMed